Status:
RECRUITING
Using Bitter Taste Receptor Blockers to Improve the Palatability of Pediatric Medicines
Lead Sponsor:
Monell Chemical Senses Center
Collaborating Sponsors:
NIAID, Division of AIDS (contract funder)
Advanced Biosciences Laboratories (ABL; primary contract holder)
Conditions:
Healthy Adults
Eligibility:
All Genders
18-60 years
Phase:
NA
Brief Summary
Many people, particularly small children, must take drugs in liquid form because they cannot swallow pills or capsules. The bad taste of some liquid drugs can keep patients from taking drugs they need...
Eligibility Criteria
Inclusion
- Between the ages of 18 and 60;
- Generally healthy by self-report;
- All races/ethnicities, both men and women;
- Able to provide informed consent;
- Able to attend repeated visits to Monell for sensory testing;
- Willing to follow instructions (e.g., refrain from eating or drinking for at least 1 hour before sessions, willing to remain on site for one hour after tasting an API that the participant has never tasted before). -
Exclusion
- Under 18 or over 60;
- Pregnant, nursing, or plans to become pregnant;
- Unable to provide consent (including limited ability to understand written and spoken English);
- Tobacco, vape, marijuana, or tetrahydrocannabinol cartridge users. We will accept people who have used tobacco or marijuana products on occasion, but not regular users;
- Known drug or food allergies of any kind;
- Diabetes or other metabolic disorder;
- Liver issues of any kind, including viral hepatitis;
- Kidney issues of any kind;
- Other chronic illness, including cardiovascular, neurological, immune disorders, or any other serious acute or chronic condition
- Dentures or other major dental implants;
- Condition affecting the oral cavity, including dry mouth, burning mouth syndrome, active sores or blisters, geographic tongue, or other disorders
- Current infection or cold, flu, or infection with SARS-CoV-2 within the last four weeks;
- Unable to taste or smell
- Daily use, or use within the last four weeks, of either prescription or over-the-counter medications (except for birth control)
- History of tuberculosis (including latent tuberculosis), positive skin or other tuberculosis test at any time in the past, birth in or residence in a country with high tuberculosis rates, known contact with someone who is tuberculosis positive
- HIV infection
Key Trial Info
Start Date :
March 18 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2026
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06929455
Start Date
March 18 2025
End Date
November 1 2026
Last Update
April 16 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Monell Chemical Senses Center
Philadelphia, Pennsylvania, United States, 19104